Clinical Trial Finder
Articulatory Adaptation Following Oral Cancer Treatment
Study Purpose
The goal of this longitudinal study is to learn more about the articulatory consequences of surgical oral cancer treatment. The main aims are to study the coordination and development of speech articulation of patients who will undergo surgical treatment for oral cancer longitudinally and whether individual differences in the reliance on auditory or tactile information can predict the success of speech compensatory strategies. Participants will perform multiple speech tasks while motion tracking sensors track the articulatory gestures.
Recruitment Criteria
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
Inclusion Criteria:
1. Diagnosed with T1 or T2 tumor in the oral cavity. 2. At least 18 years old and able to provide informed consent. 3. Native speaker of Dutch. 4. Has nog been treated for oral cancer before.Exclusion Criteria:
1a. Recurrence of disease (for patients) 1b. Treated for oral cancer (for healthy controls) 2. Speech problems (e.g., stuttering) 3. Problems with sight or hearing that impede reading or understanding instructions. When glasses or a hearing aid resolve these problems, then participants are not excluded. 4. Neurological or psychological disorders (e.g., stroke) 5. Non-removable metal in, on or around the head (piercings, braces, pacemaker, electrodes) 6. Self-reported signs of depressionTrial Details
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
The person who is responsible for the scientific and technical direction of the entire clinical study.
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
The disease, disorder, syndrome, illness, or injury that is being studied.
Arms
: Individuals treated for oral cancer
Dutch native speakers (18+) who will undergo surgical treatment for a T1 or T2 tumour on the tongue.
: Control speakers
Dutch native speakers (18+) without self-reported speech problems.
Interventions
Other: - Electromagnetic Articulography
Motion tracking sensors will track articulatory movements of the tongue, jaw and lips
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
International Sites
Status
Recruiting
Address
Faculty of Arts, University of Groningen
Groningen, , 9712 EK
Site Contact
Thomas Tienkamp, MA
[email protected]
+31 50 36 37051
Status
Recruiting
Address
University Medical Centre Groningen
Groningen, , 9713 GZ
Site Contact
Thomas Tienkamp, MA
[email protected]
+31 50 36 37051
Privacy Overview